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Summary 
Cytotoxic T  lymphocytes (CTLs) are a critical component of the immune response to tumors. 
Tumor-derived peptide antigens targeted by CTLs are being defined for several human tumors 
and  are  potential  imrnunogens  for the  induction  of specific  antitumor  immunity.  Dendritic 
cells  (DC)  are  potent  antigen-presenting  cells  (APCs)  capable  of priming  CTL  responses  in 
vivo. Here we show that major histocompatibility complex class  I-presented peptide  antigen 
pulsed onto dendritic APCs induces protective immunity to lethal challenge by a tumor trans- 
fected with the antigen gene. The immunity is antigen specific, requiring expression of the an- 
tigen gene by the tumor target,  and is eliminated  by in vivo depletion  of CD8 + T  cells.  Fur- 
thermore,  mice  that  have  rejected  the  transfected  tumor  are  protected  from  subsequent 
challenge with the untransfected parent tumor. These results suggest that immunization strate- 
gies using antigen-pulsed DC may be useful for inducing tumor-specific immune responses. 
C 
TLs are a critical component of host immunity to tu- 
mors (1-3). CTLs typically recognize peptides derived 
from endogenously synthesized proteins  and presented  by 
MHC  class I molecules on the surface of target ceils (4, 5). 
Peptides recognized by tumor-specific CTLs are being de- 
fined for several human tumors and MHC class I alleles (6-8). 
Though  the  recognition  of peptide-class  I  complexes  is 
sufficient  to  trigger  target  cell  lysis,  priming  of CTL  re- 
sponses requires the presentation of the relevant antigen by 
professional  APCs  capable  of providing  "costimulation." 
Dendritic cells (DC) are efficient APCs for CTL induction 
and may be an attractive adjuvant for immunizations using 
peptide  tumor  antigens  (9-13).  Recent  advances  have 
made it feasible to acquire significant numbers of DC from 
a variety of sources, including human peripheral blood (13, 
14)  and  murine  bone  marrow  (15-17).  Furthermore,  cell 
surface  class  I  molecules  on DC  are  accessible  to  exoge- 
nously added peptides in vitro. DC pulsed with peptides in 
vitro  present  functional  peptide-class  I  complexes  on  the 
cell surface  and  can stimulate  antigen-specific  CTL when 
administered  in  vivo  (18-23).  Here  we  show  that  DC 
pulsed  with  peptide  antigen  in  vitro  and  administered  to 
animals s.c. induce antigen-specific, CTL-mediated protec- 
tion against a lethal tumor challenge. 
Materials and Methods 
Mice  and  Cell  Lines.  Female  C57BL/6  mice.  5-8  wk  old, 
were purchased from The Jackson Laboratory (Bar Harbor, ME) 
and housed at  the  Central  Animal Facility  of the University of 
Pittsburgh. EL4 is a C57BL/6 T  thymoma and EG7 is a chicken 
egg OVA-expressing subclone of EL4 (24). B16, the C57BL/6- 
derived melanoma, was obtained from the American Type Cul- 
ture C611ection (ATCC, Rockville, MD). MO5 was constructed 
by transfection  of B16 with the pAc-neo-OVA plasmid as previ- 
ously described  (24, 25). 
Antigen  and  Antibodies.  The  peptide  corresponding  to  the 
amino acid sequence of OVA residues 257-264 (SIINFEKL) (26, 
27) (K  b restricted)  was synthesized by the Peptide Synthesis Facil- 
ity of the University of Pittsburgh Medical  Center.  mAbs were 
prepared from the hybridomas GK1.5  (anti-CD4,  ATCC TIB- 
207),  2.43  (anti-CD8,  ATCC  TIB-210)  or 30-H12  (anti-Thy 
1.2,  ATCC  TIB-107).  Ascites  containing  anti-CD8  antibodies 
were  raised  in BALB/c nu/nu  mice by i.p,  injection of GK1.5 
cells (3 ￿  106) and IFA (0.5 ml/mouse). 
Preparation Of DC.  DC were prepared from bone marrow by 
described  techniques  (15). Briefly,  bone marrow cells were de- 
pleted  of lymphocytes and  cultured  overnight  in  RPMI-1640 
supplemented with 10% FCS, t-glutamine, antibiotics,  and 2-ME 
in 24-well plates at 106 cells/well.  Cells were replated  on day 1 at 
2.5  ￿  l0  s cells/well  with GM-CSF (103 U/m[; Sigma Chemical 
Co.,  St.  Louis,  MO)  and  murine  rlL-4  (103 U/ml;  Genzyme 
Corp.,  Cambridge,  MA),  and  loosely adherent  cells were  har- 
vested on day 8. By flow cytometric analysis, these DC expressed 
CD45, CD44, CD1 lb (Mac-l), CD18, CD80, CD86, and class I 
and class II MHC antigens  (data not shown). DC were pulsed for 
2 h at 37~  with or without OVA peptide (20 ng/ml) +  ]32-mi- 
croglobulin ([]32M  ] 10 p,g/ml, human; Sigma Chemical Co.) (28) 
in reduced serum media  (Optimem;  Gibco Laboratories,  Grand 
Island, NY). Cells were then washed extensively,  resuspended  in 
PBS, and irradiated  (2,000 rad) before injection into naive mice. 
Protection  Assays.  C57BL/6  mice  were  immunized  s.c.  in 
both lower flanks with  either peptide-pulsed  DC or nonpulsed 
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boosted on day 7.7-10 d later, mice were challenged by intrader- 
mal (i.d.). injection in the midflanks bilaterally with MO5 or B16 
(2.5  ￿  104/100 Ixl/side) in PBS. Injected cells were >95% viable 
as determined by trypan blue exclusion.  In some experiments,  in 
vivo CD8 depletion was carried out by i.p. injection of ascites (1 
mg/ml, 200  Ixl/mouse)  into mice on days 7 and 9 after the final 
immunization. The size of the tumors was  assessed three times 
weekly and recorded as tumor area (mm  2) by measuring the larg- 
est perpendicular diameters.  Data are reported as the average tu- 
mor area  --_ SEM.  Survival is recorded as the percentage  of sur- 
viving animals. Mice were killed in accordance  with established 
guidelines.  All experiments included five  mice  per  group  and 
were  repeated  at  least three  times.  In some  experiments, mice 
surviving an initial MO5 challenge were rechallenged  (along with 
naive control mice) with the parent B16  (2.5 ￿  104/100  Ixl/side 
in PBS). 
Cytotoxicity  Assays.  Splenocytes  (30  ￿  106) harvested  from 
mice 7-10  d  after  the  last immunization were  restimulated by 
coculture with mitomycin C-treated EG7 cells (7.5 X  106) and 
effector  cells harvested  5  d  later.  Cytotoxicity assays were per- 
formed as described (28) with minor modifications.  Briefly, target 
cells were labeled by incubation in RPMI (10% FCS) with 51Cr 
(100 IxCi; NEN, Boston, MA) for 18 h at 37~  washed  exten- 
sively, and cocultured at 2 X 104 cells/well with effector cells (at 
the  ratios  given in the  figures) in 96-well round-bottom plates 
(200  p,1/well) for 4  h  at  37~  In some cases the  effector  cells 
were depleted of T  cell subsets using mAb plus complement be- 
fore assay as described  (29). 100 Ixl of supernatants from triplicate 
cultures was collected  and counted. Data points are expressed as 
the  mean percent specific release  of SlCr from target  cells and 
were calculated as described (27). 
Results  and Discussion 
To determine the capacity of peptide-pulsed DC to in- 
duce protective immunity, we used a  tumor model based 
on  the  poorly  immunogenic  C57BL/6  mouse-derived 
melanoma  B16  and  the  OVA-transfected  B16  subclone 
MO5. MO5 endogenously synthesizes OVA and generates 
and presents the  OVA peptide SIINFEKL with its surface 
class I molecule K b (25). The expression of the OVA anti- 
gen does not significantly increase the immunogenicity of 
this tumor in vivo as tumor growth and progression is sim- 
ilar to that of the untransfected parent tumor (25). 
In initial experiments, we evaluated the capacity of OVA 
peptide-pulsed DC  to  induce CTLs capable of lysing the 
OVA-expressing melanoma in vitro. Bone marrow-derived 
DC (15) were prepulsed with SIINFEKL in the presence of 
exogenously added ~2M and washed extensively. Peptide- 
pulsed  DC  specifically stimulated the  SIINFEKL  +  K b- 
specific T-T hybridoma RF33.70 (27),  indicating the pres- 
ence of functional SIINFEKL +  K b complexes on the DC 
surface (data not shown). The peptide-pulsed DC were ir- 
radiated and injected s.c. into naive mice. Immunized mice 
were  boosted  7  d  later.  In vitro  restimulated spleen cells 
from these mice lysed the OVA transfectant MO5, but not 
the untransfected parent melanoma B16  (Fig.  1 A).  Simi- 
larly, these effector cells lysed the OVA-expressing murine 
thymoma EG7 (Fig. 1 B),  but not the untransfected parent 
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Figure  1.  hnmunization with OVA peptide-pulsed DC induces anti- 
gen-specific CD8 + effector cells that lyse OVA-expressing  tumor targets. 
(A) C57BL/6 mice were immunized  s.c. in the lower flanks  with peptide- 
pulsed DC or PBS (not shown) on days 0 and 7. Splenocytes  taken 7 d 
after the last immunization  were restimulated  in vitro for 5 d with mito- 
mycin C-treated OVA-expressing EG7  cells and assayed for cytolytic 
function against  51Cr-labeled  B16 melanoma (open squares)  or MO5 (solid 
squares).  (B) Effector populations  were incubated with complement  alone 
(solid circles) or with nLAbs against CD4  + (open  triangles),  CD8 + (open  cir- 
cles), or Thy 1.2 + (solid  triangles)  lymphocytes  and complement, then as- 
sayed for cytolytic  activity  against  EG7 cells. Specific release for EL4 tar- 
gets in B was 5, 3, and 0% at E/T ratios of 30, 10, and 3: 1. 
tumor EL4 (Fig.  1). Thus tumor cell lysis was antigen spe- 
cific, depending on expression of OVA by the tumor tar- 
get.  Depletion of T  cell subsets from effector populations 
using  mAbs  demonstrated  that  lysis  depended  on  Thy 
1+CD8 +  subsets  characteristic  of MHC  class  I-restricted 
CTL effector cells (Fig. 1 B). These results are in agreement 
with those recently reported by Porgador and Gilboa (23) 
demonstrating  CTL  priming  after  i.v.  administration of 
peptide-pulsed DC. 
To determine the capacity of peptide-pulsed DC to in- 
duce  protective  tumor  immunity, groups  of mice  were 
subcutaneously immunized with  SIINFEKL-pulsed DC, 
boosted 7  d  later, and then challenged i.d. at a distant site 
with  the  MO5  melanoma.  Immunized mice  were  pro- 
tected  from  tumor  growth  locally  (Fig.  2  A)  and  from 
death  (Fig.  2  C).  Tumors  in  control  mice  (PBS  immu- 
nized) grew progressively (Fig. 2 A) and were lethal (Fig. 2 
C). Mice immunized with DC not pulsed with SIINFEKL 
were not protected  (Fig. 2,  B and D), suggesting that sub- 
cutaneously injected DC  do  not induce tumor immunity 
by  antigen-independent mechanisms in  this  model.  It  is 
also unlikely that protection was the result of carryover of 
free SIINFEKL, as the peptide-pulsed DC were extensively 
washed  before  injection, and peptide  with  [32M  alone is 
not protective when injected subcutaneously without DC 
(Fig.  2,  B  and  D).  Furthermore,  mice  immunized with 
SIINFEKL-pulsed DC were not protected from challenge 
with the untransfected parent B16 (Fig. 3,  B and E), indi- 
cating that protective immunity was  antigen specific,  de- 
pending on OVA expression by the tumor target.  Finally, 
we evaluated the contribution of CD8 + T  cells to this pro- 
tective tumor immunity by depleting groups of immunized 
or  control  animals  of CD8"  effector  cells  before  tumor 
challenge by repeated i.p. injection of anti-CD8 mAb (25, 
30).  Tumor growth  and survival in immunized CD8-  T 
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Figure  2.  Inmmnization  with peptide-pulsed  DC  induces  protective 
immunity to  lethal  tumor  challenge.  C57BL/6  mice were  immunized 
twice with PBS (open  squares),  peptide-pulsed  DC (solid  squares),  peptide 
+  ~2M (open  triangles),  or DC alone (solid triangles)  on days 0 and 7. Mice 
were challenged with MO5 7 d after the last immunization  (5 ￿  104 cells/ 
mouse,  i.d.,  bilateral, midflanks) (day 0).  Tumor size (A and B) was as- 
sessed three  times per week and is reported as the average tumor area in 
square millimeters until the first death occurred in each group. Survival (C 
and D) is recorded as the percentage of surviving animals. All experiments 
included five mice per group. Mice becoming moribund were killed. 
cell-depleted animals  was  similar to  that  observed in  non- 
immunized controls, with or without T  cell depletion (Fig. 
3,  A,  C,  D  and  F).  Therefore,  CD8 +  T  cells are  essential 
for  the  protective  tumor  immunity  induced  by  peptide- 
pulsed DC  in this model. 
Interestingly,  immunized  mice  that  had  rejected  MO5 
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Figure 4.  Immunization  with peptide-pulsed  DC and challenge with 
MO5 induces long-lasting protective immunity to B16. Naive mice (open 
circles) and surviving mice that had been immunized with peptide-pulsed 
DC  (46  d  previously)  and  challenged  (solid  circles) as described  (Fig. 2) 
were  rechallenged  with  the  parental  B16  melanoma  (5  ￿  104  cells/ 
mouse, i.d., bilateral, midflanks) (day 0). Survival is recorded  as described 
(Fig. 2).  Each  group  contained  five mice.  Experiments  were repeated 
three times, and a representative experiment  is shown. Mice that appeared 
moribund were killed. 
were  protected  from  subsequent  tumor  challenge  by  the 
untransfected  parent B16  (Fig. 4).  Presumably,  mice reject- 
ing  the  OVA-transfected  melanoma  developed  immunity 
to other antigens expressed on MO5  and "shared" with the 
untransfected  parent  melanoma.  Induction  of immunity  to 
shared tumor antigens has also been observed in this tumor 
model during tumor rejection after particulate  antigen im- 
munization  (25).  Immune  responses  to  additional,  unde- 
fined shared tumor antigens should augment antitumor im- 
munity  induced  using  defined  antigens.  Similarly,  it  may 
also be possible to induce immunotherapeutic  responses by 
immunizing  tumor-bearing  hosts  with  DC  pulsed  with  a 
potent peptide  antigen and subsequently  immunizing with 
their own killed tumor cells that have been transfected with 
Figure 3.  Tumor immunity induced by pep- 
tide-pulsed  DC  is  antigen  specific  and  CTL 
mediated.  C57BL/6  mice  were  immunized 
twice with PBS (open symbols) or peptide-pulsed 
DC  (solid symbols)  on days 0 and 7. Some mice 
were depleted  of CD8 + T lymphocytes  by i.p. 
injection  of anti-CD8 mAb 7 and 9 d after the 
last immunization  (C and F). Mice were chal- 
lenged with MO5 (,4, C, D, and F) or B16 (B 
and E) as described  (Fig. 2)  10 d after the last 
immunization  (day 0).  Tumor size (A-C) and 
survival (D-F) were recorded  as described (Fig. 
2).  All  experiments  included  five  mice  per 
group  and  were repeated  at  least three  times. 
Mice becoming moribund were killed. 
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285  Celluzzi et al.  Brief Definitive Report the antigen gene. This approach may be particularly signif- 
icant for patients with tumors whose tumor rejection anti- 
gens have not yet been defined. 
Several observations suggest  that  DC  play a  role in  tu- 
mor immunity (31). Histologic infiltration of DCs into hu- 
man  tumors  has  been  correlated with  reduced  metastatic 
disease and prolonged survival (32-36).  In murine models, 
DC  pulsed  with  tumor  cell  lysates  can  stimulate  CD4- 
mediated  antitumor  immunity  in  vivo  (37-40).  To  our 
knowledge, our studies are the first demonstration of CD8- 
mediated antitumor  immunity  induced by antigen-pulsed 
DC.  Immunization  with  peptide  alone  or with  adjuvants 
can  induce  antitumor  immunity in  murine  models and  is 
being evaluated in humans  (41).  Using DC  as an adjuvant 
for  peptide  delivery  has  potential  advantages  over  other 
forms  of peptide  delivery  in  that  peptide  in  preformed 
complexes with class I on the surface of the DC is likely to 
be  presented  in  the  appropriate  APC  context  for  T  cell 
stimulation and will be protected from degradation by ex- 
tracellular proteases (42). It is possible that DC pulsing with 
a  combination  of tumor  cell lysates, which  are  processed 
and  presented  through  the  MHC  class II-restricted path- 
way,  and  peptide  antigens  capable  of forming  complexes 
with cell surface class I molecules could enhance immunity 
by providing synergistic CD4- and CD8-mediated tumor- 
specific immunity. 
DC  used in our study were derived from bone marrow 
cultured in the presence of GM-CSF and IL-4 and express 
high levels of costimulatory molecules  (15).  When  pulsed 
with  peptides,  these  DC  are  more  potent  immunogens 
than bone marrow DC  cultured in GM-CSF and TNF-cx 
or GM-CSF  alone  (43).  Interestingly, human  DC  can be 
readily obtained  from  peripheral  blood  by  short-term  in 
vitro culture with GM-CSF and IL-4 (13,  14).  These hu- 
man  DC  are  phenotypically similar to  those  used  in  our 
study and can  elicit potent antitumor  CTL  in vitro when 
pulsed with the relevant peptide (44). This may be signifi- 
cant for translational studies designed to  induce immunity 
to human tumors. 
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